The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1314
Milnacipran (Savella) for Fibromyalgia
The full article is available to subscribers Subscriber Login   
Revised 7/8/09: Milnacipran article: In the 2nd sentence, “similar to gabapentin” was added. It now reads, “...a gamma-aminobutyric acid (GABA) analog similar to gabapentin...”

Milnacipran (Savella – Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gamma-aminobutyric acid (GABA) analog similar to gabapentin also approved for treatment of diabetic neuropathy, post-herpetic neuralgia and epilepsy,1 and duloxetine, an SNRI also approved for treatment of depression, diabetic neuropathy and generalized anxiety disorder.2

FIBROMYALGIA — Fibromyalgia is characterized by chronic musculoskeletal pain, tenderness, fatigue and sleep disturbance. Genetic, environmental and psychosocial factors appear to influence its expression.3-5

In addition to the FDA-approved drugs, medications used to treat fibromyalgia have included analgesics, muscle relaxants, anticonvulsants, and antidepressants ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Milnacipran (Savella) for Fibromyalgia
Article code: 1314b
 Electronic, downloadable article - $25